• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型基于酒石酸盐的 TNF-α转化酶(TACE)抑制剂的发现。

The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.

机构信息

Department of Medicinal Chemistry, Schering-Plough Research Institute Cambridge, 320 Bent Street, Cambridge, MA 02141, United States.

出版信息

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1189-93. doi: 10.1016/j.bmcl.2009.12.004. Epub 2009 Dec 5.

DOI:10.1016/j.bmcl.2009.12.004
PMID:20022498
Abstract

A novel series of TNF-alpha convertase (TACE) inhibitors which are non-hydroxamate have been discovered. These compounds are bis-amides of L-tartaric acid (tartrate) and coordinate to the active site zinc in a tridentate manner. They are selective for TACE over other MMP's. We report the first X-ray crystal structure for a tartrate-based TACE inhibitor.

摘要

现已发现一系列新型 TNF-α 转化酶(TACE)抑制剂,它们均不属于羟胺类。这些化合物是 L-酒石酸(酒石酸盐)的双酰胺,以三齿配位方式与活性部位锌配位。它们对 TACE 的选择性高于其他 MMP。我们报告了首个基于酒石酸盐的 TACE 抑制剂的 X 射线晶体结构。

相似文献

1
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.新型基于酒石酸盐的 TNF-α转化酶(TACE)抑制剂的发现。
Bioorg Med Chem Lett. 2010 Feb 1;20(3):1189-93. doi: 10.1016/j.bmcl.2009.12.004. Epub 2009 Dec 5.
2
Structure and activity relationships of tartrate-based TACE inhibitors.基于酒石酸盐的 TACE 抑制剂的结构与活性关系。
Bioorg Med Chem Lett. 2010 Aug 15;20(16):4812-5. doi: 10.1016/j.bmcl.2010.06.104. Epub 2010 Jun 25.
3
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.基于 2-(2-氨噻唑-4-基)吡咯烷的酒石酸盐双酰胺作为强效、选择性和口服生物利用度的 TACE 抑制剂。
Bioorg Med Chem Lett. 2011 May 15;21(10):3172-6. doi: 10.1016/j.bmcl.2011.01.002. Epub 2011 Jan 6.
4
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).肿瘤坏死因子-α转化酶(TACE)低纳摩尔非羟肟酸抑制剂的发现。
Bioorg Med Chem Lett. 2007 Jan 1;17(1):266-71. doi: 10.1016/j.bmcl.2006.09.048. Epub 2006 Oct 5.
5
Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.新型基质金属蛋白酶-13 抑制剂的合成、初步生物学评价及分子模拟。
Eur J Med Chem. 2011 Nov;46(11):5549-55. doi: 10.1016/j.ejmech.2011.09.018. Epub 2011 Sep 21.
6
Chemical-physical analysis of a tartrate model compound for TACE inhibition.对 TACE 抑制的酒石酸盐模型化合物进行化学-物理分析。
Phys Chem Chem Phys. 2013 Nov 21;15(43):18881-93. doi: 10.1039/c3cp52955j.
7
The conformational landscape of tartrate-based inhibitors of the TACE enzyme as revealed by Hamiltonian Replica Exchange simulation.基于 Hamiltonian Replica Exchange 模拟揭示的 TACE 酶的酒石酸盐类抑制剂的构象景观。
Phys Chem Chem Phys. 2013 Jun 21;15(23):9186-96. doi: 10.1039/c3cp00108c. Epub 2013 May 7.
8
Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
Bioorg Med Chem Lett. 2009 Jan 1;19(1):54-7. doi: 10.1016/j.bmcl.2008.11.034. Epub 2008 Nov 14.
9
Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.新型 TNF-α 转化酶(TACE)抑制剂作为治疗炎症性疾病的潜在药物。
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7283-7. doi: 10.1016/j.bmcl.2010.10.081. Epub 2010 Oct 23.
10
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.新型异羟肟酸酯作为高效肿瘤坏死因子-α转化酶抑制剂的发现:第一部分——两种结合模式的发现。
J Med Chem. 2008 Feb 28;51(4):725-36. doi: 10.1021/jm070376o. Epub 2008 Feb 5.

引用本文的文献

1
A workflow to create a high-quality protein-ligand binding dataset for training, validation, and prediction tasks.一种用于创建高质量蛋白质-配体结合数据集以进行训练、验证和预测任务的工作流程。
Digit Discov. 2025 Apr 2;4(5):1209-1220. doi: 10.1039/d4dd00357h. eCollection 2025 May 14.
2
In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators.基于 ADAM17 的计算机模拟和实验动力学建模作为未来调节剂筛选系统的基础。
Int J Mol Sci. 2022 Jan 25;23(3):1368. doi: 10.3390/ijms23031368.
3
Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study.
维生素D3通过靶向miRNA - 145和ADAM17预防睾丸扭转对睾丸的有害影响:计算机模拟和体内研究
Pharmaceuticals (Basel). 2021 Nov 25;14(12):1222. doi: 10.3390/ph14121222.
4
Targeting Metalloenzymes for Therapeutic Intervention.靶向金属酶治疗干预。
Chem Rev. 2019 Jan 23;119(2):1323-1455. doi: 10.1021/acs.chemrev.8b00201. Epub 2018 Sep 7.
5
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.一种新型 ADAM17 抑制剂通过体外和体内逆转 Notch 和上皮-间充质转化使结直肠癌细胞对 5-氟尿嘧啶敏感。
Cell Prolif. 2018 Oct;51(5):e12480. doi: 10.1111/cpr.12480. Epub 2018 Aug 2.
6
In Search of Selectivity in Inhibition of ADAM10.寻找ADAM10抑制的选择性
ACS Med Chem Lett. 2018 Jun 11;9(7):708-713. doi: 10.1021/acsmedchemlett.8b00163. eCollection 2018 Jul 12.
7
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate.利用结合外位点的糖基化底物发现ADAM10的一种酶和底物选择性抑制剂。
Sci Rep. 2016 Dec 5;6(1):11. doi: 10.1038/s41598-016-0013-4.
8
Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode.发现具有独特铰链结合模式的新型CHK1激酶抑制剂系列。
ACS Med Chem Lett. 2012 Jan 20;3(2):123-8. doi: 10.1021/ml200249h. eCollection 2012 Feb 9.
9
Molecular Descriptors in Modelling the Tumour Necrosis Factor-α Converting Enzyme Inhibition Activity of Novel Tartrate-Based Analogues.基于酒石酸盐的新型类似物肿瘤坏死因子-α转化酶抑制活性建模中的分子描述符
Indian J Pharm Sci. 2013 Jan;75(1):36-44. doi: 10.4103/0250-474X.113539.
10
Rational approaches to improving selectivity in drug design.提高药物设计选择性的合理方法。
J Med Chem. 2012 Feb 23;55(4):1424-44. doi: 10.1021/jm2010332. Epub 2012 Jan 12.